Sergio A. Giralt, MD, discusses how he selects patients with chronic graft-vs-host disease (cGVHD) for treatment with ...

Sergio A. Giralt, MD, discusses the key results from recent chronic graft-vs-host disease (cGVHD) research presented at ASH ...

Sergio A. Giralt, MD, discusses how he uses cyclophosphamide to treat patients with chronic graft-vs-host disease (cGVHD), ...

Glaucoma can cause damage to the optic nerve if left untreated, making frequent eye appointments vital for catching it ...

This meta-analysis sheds more light on the beneficial impact of multiple melanoma (MM) treatments and the predictive value of ...

Sergio A. Giralt, MD, discusses how rituximab plays a key role in treating chronic graft-vs-host disease. It is often used in combination with ibrutinib to enhance therapeutic outcomes. He reviews the ...

The panelist discusses how recurrent Clostridioides difficile infection significantly increases health care costs through prolonged hospitalizations, complex treatments, and elevated medical resource ...

Adalimumab and secukinumab are the only FDA-approved biologic drugs to treat hidradenitis suppurativa, limiting options for ...

Common measurements for modified adeno-associated viruses (AAVs), a gene therapy delivery method, showed substantial ...

Secukinumab delivers sustained efficacy and quality of life improvements in pediatric generalized pustular psoriasis (GPP).

Latine individuals in the US face higher morbidity and mortality in skin cancer outcomes despite lower lifetime risk.

Tiago Biachi, MD, PhD, highlighted the transformative role of personalized medicine in gastrointestinal (GI) cancer treatment through advances in next-generation sequencing and circulating tumor DNA, ...